Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of ctDNA-based ESR1 testing in breast cancer: results from the first external quality assessment scheme in China.

Expert review of molecular diagnostics - 1 Jun 2025

Lin Guigao, Li Jing, Zhang Kuo

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) testing of plasma for ESR1 somatic variants is essential for guiding treatment decisions in hormone receptor-positive (HR + ) and HER2-negative (HER2-) advanced or metastatic breast cancer (MBC) patients who have progressed on frontline therapy. To ensure optimal, uniform, and reliable ESR1 testing across China, an pilot external quality assessment (EQA) scheme was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms
Share to China

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Estrogen Receptor alpha

Share to Genotype

Share to Mutation

Share to Quality Assurance, Health Care

Source

Identifiers

PMID: 40277432
DOI: 10.1080/14737159.2025.2498542

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of ctDNA-based ESR1 testing in breast cancer: results from the first external quality assessment scheme in China.PMID 40277432Read ↗

Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.Semantic proximity Read ↗

ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.Semantic proximity Read ↗

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.Semantic proximity Read ↗

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.Semantic proximity Read ↗

Thirteen Years of an International External Quality Assessment Scheme for Genotyping: Results and Recommendations.Semantic proximity Read ↗

ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.Semantic proximity Read ↗

Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.Semantic proximity Read ↗

Super-ARMS: A new method for plasma ESR1 mutation detection.Semantic proximity Read ↗

Results of a worldwide External Quality Assessment of cfDNA testing in Lung CancerSemantic proximity Read ↗

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Semantic proximity Read ↗

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.Semantic proximity Read ↗

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.